Secondary prevention in concurrent coronary artery, cerebrovascular, and chronic kidney disease: focus on pharmacological therapy [0.03%]
冠心病、脑血管病和慢性肾脏病并存的二级预防——药疗方面需注意的问题
Lawrence A Notaro,Mohammed H Usman,James F Burke et al.
Lawrence A Notaro et al.
Patients with coronary artery disease (CAD) commonly have varying degrees of coexisting cerebrovascular disease (CVD) and chronic kidney disease (CKD), and proper management is complicated partly because of a lack of unifying guidelines. Th...
William Wilson,Ronen Gurvitch,Andrew E Ajani
William Wilson
The antiplatelet drug prasugrel is one of the new generations of thienopyridines, drugs that inhibit the platelet P2Y(12) receptor. It is becoming clear that there is variability in individual responses to antiplatelet agents such as clopid...
Neuroendocrine effects on the heart and targets for therapeutic manipulation in heart failure [0.03%]
神经内分泌对心脏的影响及心力衰竭的治疗靶点
Parminder S Chaggar,Chris J Malkin,Steven M Shaw et al.
Parminder S Chaggar et al.
Chronic heart failure (CHF) involves derangements in multiple neurohormonal axes leading to a procatabolic state and wasting syndrome associated with significant mortality. Catabolic abnormalities include excess catecholamines and glucocort...
The effect of beta-blockers on the adaptive immune system in chronic heart failure [0.03%]
β受体阻滞剂对慢性心力衰竭适应性免疫系统的影响
Steven M Shaw,Teresa Coppinger,Carolyn Waywell et al.
Steven M Shaw et al.
It remains possible that the benefit from beta-blockers (BBs) in chronic heart failure (CHF) may not entirely be derived from a class-specific effect. Several experimental reports have alluded to the capability of immunomodulation by indivi...
Differences in medical treatment of chronic coronary heart disease patients according to medical specialities [0.03%]
不同专业医师对慢性冠心病患者药物治疗的差异性分析
Alberto Cordero,Vicente Bertomeu-Martínez,Pilar Mazón et al.
Alberto Cordero et al.
Coronary heart disease (CHD) patients are currently attended by many different medical specialities. CHD patients must achieve the highest grade of treatment implementation and risk factors control. The aims were to describe differences in ...
Zanfina Ademi,Danny Liew,Derek Chew et al.
Zanfina Ademi et al.
Australia's Pharmaceutical Benefits Scheme supports the use of effective drugs for the prevention and control of cardiovascular risk factors. However, there are little data available describing per person costs of medication in primary prev...
Antihypertensive drugs and new-onset diabetes: a retrospective longitudinal cohort study [0.03%]
抗高血压药与新发糖尿病：回顾性纵向队列研究
Gwo-Ping Jong,Mu-Hsin Chang,Liyun Tien et al.
Gwo-Ping Jong et al.
Antihypertensive drugs have been linked to new-onset diabetes (NOD); however, data on the effect of these drugs on the development of NOD in hypertensive patients has not been well determined. We aimed to investigate the association between...
Valsartan improves endothelial dysfunction in hypertension: a randomized, double-blind study [0.03%]
valsartan改善高血压患者血管内皮功能紊乱的疗效研究——一项随机双盲临床试验
Nikolaos Tzemos,Pitt O Lim,Thomas M MacDonald
Nikolaos Tzemos
Endothelial dysfunction can predict cardiac outcomes in hypertension and reversing this abnormality has become an attractive therapeutic objective. We tested the hypothesis that blocking the angiotensin type 1 (AT(1)) receptor with valsarta...
Randomized Controlled Trial
Cardiovascular therapeutics. 2009 Fall;27(3):151-8. DOI:10.1111/j.1755-5922.2009.00085.x 2009
Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist [0.03%]
ticagrelor：第一个可逆性结合的口服P2Y12受体拮抗剂
Steen Husted,J J J van Giezen
Steen Husted
Ticagrelor (AZD6140) is the first reversibly binding oral P2Y(12) receptor antagonist that blocks ADP-induced platelet aggregation. Unlike thienopyridines, which irreversibly bind to the P2Y(12) receptor for the lifetime of the platelet, ti...
Prescribing statins to patients with nonalcoholic fatty liver disease: real cardiovascular benefits outweigh theoretical hepatotoxic risk [0.03%]
非酒精性脂肪肝病患者的他汀类药物处方：实际心血管益处大于理论上的肝毒性风险
P Riley,M Al Bakir,J O&#x;Donohue et al.
P Riley et al.
Statins are among the most widely prescribed drugs in the western world and play a significant role in reducing cardiovascular risk. However, concern regarding their hepatic safety profile has meant that patients with concurrent liver patho...